{
    "nctId": "NCT03972696",
    "briefTitle": "OPTimizing Irradiation Through Molecular Assesment of Lymph Node After Primary Systemic Treatment",
    "officialTitle": "OPTimizing Irradiation Through Molecular Assesment of Lymph Node After Primary Systemic Treatment",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 32,
    "primaryOutcomeMeasure": "To show the non-inferiority of (BA2) compared to (BA3S), in terms of 5-years diseasefree survival (DFS), including the local, regional and distant disease free survival and excluding second neoplasms",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Infiltrating carcinoma of the breast.\n* Metastatic lymph nodes (N1) at diagnosis, as determined histologically by Fine Needle Aspiration or Core Needle Biopsy.\n* Primary systemic therapy (including antiestrogen or chemotherapy, and targeted therapies).\n* Tumour surgery: tumorectomy, quadrantectomy or mastectomy.\n* OSNA (ND) or - lymph nodes after primary systemic therapy.\n* Age \u2265 18 years old.\n* Karnofsky Index \u2265 70 %.\n* Signed Informed Consent.\n\nExclusion Criteria:\n\n* Lymphadenectomy.\n* Bilateral breast cancer.\n* Males.\n* Previous thoracic irradiation therapy.\n* Contraindications of radiotherapy (pregnancy, severe collagen diseases).\n* Other neoplasms.\n* Severe associated comorbidities that, according to the investigator criteria, may interfere with the study evaluations.\n* Lymp nodes OSNA -(L), +, ++ after primary systemic therapy.\n* Sentinel lymph node biopsy previous to the primary systemic therapy.\n* Mammary internal chain affected.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}